FDA Approves Encorafenib/Binimetinib Combo for Advanced Melanoma with BRAF Mutation
On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Read FDA announcement.
Posted June 27, 2018